Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
Humans
Hospitalization
/ statistics & numerical data
COVID-19
/ prevention & control
COVID-19 Vaccines
/ immunology
Aged
Europe
/ epidemiology
Female
Male
Middle Aged
Adult
Case-Control Studies
SARS-CoV-2
/ immunology
Vaccine Efficacy
/ statistics & numerical data
Vaccination
/ statistics & numerical data
Young Adult
Aged, 80 and over
Adolescent
COVID‐19 XBB.1.5 vaccine
Europe
SARS‐CoV‐2 hospitalisation
vaccine effectiveness
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
04
07
2024
received:
03
04
2024
accepted:
26
07
2024
medline:
15
8
2024
pubmed:
15
8
2024
entrez:
15
8
2024
Statut:
ppublish
Résumé
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13360Subventions
Organisme : European Centre for Disease Prevention and Control
ID : ECDC/2021/016
Informations de copyright
© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
European Medicines Agency, “COVID‐19 Medicines,” https://www.ema.europa.eu/en/human‐regulatory‐overview/public‐health‐threats/coronavirus‐disease‐covid‐19/covid‐19‐medicines.
European Centre for Disease Prevention and Control (ECDC), “Interim COVID‐19 Vaccination Coverage in the EU/EEA During the 2023–24 Season Campaigns,” (2024), ECDC, Stockholm, 2024, https://www.ecdc.europa.eu/en/publications‐data/interim‐covid‐19‐vaccination‐coverage‐eueea‐during‐2023‐24‐season‐campaigns.
European Centre for Disease Prevention and Control (ECDC), “Communicable Disease Threats Report, 17–23 December 2023, Week 51,” (2023), ECDC, Stockholm, 2024, https://www.ecdc.europa.eu/en/publications‐data/communicable‐disease‐threats‐report‐17‐23‐december‐2023‐week‐51.
European Centre for Disease Prevention and Control (ECDC), “Core Protocol for ECDC Studies of COVID‐19 Vaccine Effectiveness Against Hospitalisation With Severe Acute Respiratory Infection, Laboratory‐Confirmed With SARS‐CoV‐2 or With Seasonal Influenza—Version 3.0,” (2024), ECDC, Stockholm, 2024, https://www.ecdc.europa.eu/en/publications‐data/core‐protocol‐ecdc‐studies‐covid‐19‐vaccine‐effectiveness‐3.
A. Peralta‐Santos, Assessment of COVID‐19 Surveillance Case Definitions and Data Reporting in the European Union. Briefing Requested by the ENVI Committee (Brussels: European Parliament, 2020), http://www.europarl.europa.eu/RegData/etudes/BRIE/2020/652725/IPOL_BRI(2020)652725_EN.pdf.
L. Antunes, C. Mazagatos, I. Martínez‐Baz, et al., “Effectiveness of the Adapted Bivalent mRNA COVID‐19 Vaccines Against Hospitalisation in Individuals Aged ≥ 60 Years During the Omicron XBB Lineage‐Predominant Period: VEBIS SARI VE Network, Europe, February to August, 2023,” Eurosurveillance 29, no. 3 (2024): 2300708, https://doi.org/10.2807/1560‐7917.ES.2024.29.3.2300708.
European Centre for Disease Prevention and Control (ECDC), “Interim Analysis of COVID‐19 Vaccine Effectiveness Against Severe Acute Respiratory Infection due to SARS‐CoV‐2 in Individuals Aged 20 Years and Older—Fourth Update,” (2023), ECDC, Stockholm, 2024, https://www.ecdc.europa.eu/en/publications‐data/interim‐analysis‐covid‐19‐vaccine‐effectiveness‐against‐severe‐acute‐respiratory.
A. M. Rose, N. Nicolay, V. Sandonis Martín, et al., “Vaccine Effectiveness Against COVID‐19 Hospitalisation in Adults (≥20 Years) During Omicron‐Dominant Circulation: I‐MOVE‐COVID‐19 and VEBIS SARI VE Networks, Europe, 2021 to 2022,” Eurosurveillance 28, no. 47 (2023): 2300187, https://doi.org/10.2807/1560‐7917.ES.2023.28.47.2300187.
C. H. Van Werkhoven, A. W. Valk, B. Smagge, et al., “Early COVID‐19 Vaccine Effectiveness of XBB.1.5 Vaccine Against Hospitalisation and Admission to Intensive Care, the Netherlands, 9 October to 5 December 2023,” Eurosurveillance. 29, no. 1 (2024): 2300703, https://doi.org/10.2807/1560‐7917.ES.2024.29.1.2300703.
C. H. Hansen, I. R. Moustsen‐Helms, M. Rasmussen, B. Søborg, H. Ullum, and P. Valentiner‐Branth, “Short‐Term Effectiveness of the XBB.1.5 Updated COVID‐19 Vaccine Against Hospitalisation in Denmark: A National Cohort Study,” The Lancet Infectious Diseases. 24 (2024): e73–e74.
S. Y. Tartof, J. M. Slezak, T. B. Frankland, et al., “BNT162b2 XBB1.5‐Adapted Vaccine and COVID‐19 Hospital Admissions and Ambulatory Visits in US Adults,” Available in preprint from MedRxiv; posted 28 December 2023, https://doi.org/10.1101/2023.12.24.23300512v1.
J. DeCuir, “Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID‐19 Vaccines Against COVID‐19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥ 18 Years—VISION and IVY Networks, September 2023–January 2024,” MMWR. Morbidity and Mortality Weekly Report 73, no. 8 (2024): 180–188, https://doi.org/10.15585/mmwr.mm7308a5.
C. H. Hansen, “Bias In Vaccine Effectiveness Studies Of Clinically Severe Outcomes That Are Measured With Low Specificity: The Example Of COVID‐19‐Related Hospitalisation,” Eurosurveillance. 29, no. 7 (2024): 2300259, https://doi.org/10.2807/1560‐7917.ES.2024.29.7.2300259.